Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AZ Centers Pearl As The Jewel Of Its Respiratory Franchise

This article was originally published in The Pink Sheet Daily

Executive Summary

The British pharma announced its proposed acquisition of Pearl Therapeutics, adding a late-stage COPD drug to its pipeline and a triple combo therapy to its mid-stage pipeline.

You may also be interested in...



Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study

The latest drug development news and highlights from our FDA Performance Tracker.

AstraZeneca's Hudson Optimistic On Return To Growth In 2017

US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.

Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal

Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel